作　　者： ; ; ; ; ;

机构地区： 梅州市人民医院

出　　处： 《包头医学院学报》 2019年第3期31-32,35,共3页

摘　　要： 目的:紫杉醇脂质体联合表柔比星、环磷酰胺方案用于三阴性乳腺癌新辅助化疗的临床疗效分析。方法:将2014年1月至2017年1月所收治的60例三阴性乳腺癌患者作为研究对象,随机将60例患者分成两组,分别为观察组和对照组,每组各30例,观察组选用紫杉醇脂质体联合表柔比星、环磷酰胺方案行新辅助化疗,对照组则选用多西他赛+表柔比星+环磷酰胺方案。结果:观察组患者近期总有效率为86.67%,而对照组患者近期总有效率为83.33%,组间对比差异无统计学意义(P>0.05);两组患者在脱发、恶心呕吐、关节肌肉疼痛、骨髓抑制上对比差异有统计学意义(P<0.05),肝功能损害上差异无统计学意义(P>0.05)。结论:紫杉醇脂质体联合表柔比星、环磷酰胺方案对三阴性乳腺癌新辅助化疗有着较为显著的价值,值得临床研究使用。 Objective:To evaluate the clinical efficacy of paclitaxel liposome combined with epirubicin and cyclophosphamide regimen in neoadjuvant chemotherapy for triple negative breast cancer.Methods:60 patients with triple negative breast cancer treated from January 2014 to January 2017 were selected and randomly divided into observation group and control group,30 cases in each group.The observation group received neoadjuvant chemotherapy with paclitaxel liposome combined with epirubicin and cyclophosphamide,while the control group received docetaxel plus epirubicin and cyclophosphamide.Results:The short-term total effective rate was 86.67%in the observation group and 83.33%in the control group,and there was no significant difference between the two groups(P>0.05).There were significant differences in alopecia,nausea and vomiting,joint muscle pain and bone marrow suppression between the two groups(P<0.05),and there was no significant difference in liver function damage(P<0.05).Conclusion:Paclitaxel liposome combined with epirubicin and cyclophosphamide regimens have good value in neoadjuvant chemotherapy for triple negative breast cancer and are worthy of clinical application.

关 键 词： 紫杉醇脂质体 表柔比星 环磷酰胺 三阴性乳腺癌

领　　域： []